The short version of Reference standard fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-02 and is reviewed periodically as new material appears.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
=== Biology === In modern biological analysis, various kinds of organic dyes are used. However, as technology advances, greater flexibility in these dyes is sought. To this end, quantum dots have quickly filled in the role, being found to be superior to traditional organic dyes on several counts, one of the most immediately obvious being brightness (owing to the high extinction coefficient combined with a comparable quantum yield to fluorescent dyes) as well as their stability (allowing much less photobleaching). It has been estimated that quantum dots are 20 times brighter and 100 times more stable than traditional fluorescent reporters. For single-particle tracking, the irregular blinking of quantum dots is a minor drawback. However, there have been groups which have developed quantum dots which are essentially nonblinking and demonstrated their utility in single-molecule tracking experiments. The use of quantum dots for highly sensitive cellular imaging has seen major advances. The improved photostability of quantum dots, for example, allows the acquisition of many consecutive focal-plane images that can be reconstructed into a high-resolution three-dimensional image. Another application that takes advantage of the extraordinary photostability of quantum dot probes is the real-time tracking of molecules and cells over extended periods of time. Antibodies, streptavidin, peptides, DNA, nucleic acid aptamers, or small-molecule ligands can be used to target quantum dots to specific proteins on cells.
The normal function of Aβ is not yet known. Though some animal studies have shown that the absence of Aβ does not lead to any obvious loss of physiological function, several potential activities have been discovered for Aβ, including activation of kinase enzymes, protection against oxidative stress, regulation of cholesterol transport, functioning as a transcription factor, and anti-microbial activity (potentially associated with Aβ's pro-inflammatory activity). The glymphatic system clears metabolic waste from the mammalian brain, and in particular amyloid beta. A number of proteases have been implicated by both genetic and biochemical studies as being responsible for the recognition and degradation of amyloid beta; these include insulin degrading enzyme and presequence protease. The rate of removal is significantly increased during sleep. However, the significance of the glymphatic system in Aβ clearance in Alzheimer's disease is unknown.
In Portugal, public prosecution is conducted by the Public Prosecution Service which is headed by the prosecutor general. The main police organisations of Portugal are the Guarda Nacional Republicana (National Republican Guard), the Polícia de Segurança Pública (Public Security Police), a civilian police force that works in urban areas; and the Polícia Judiciária (Judiciary Police), a senior criminal police body, under the authority of the Minister of Justice and endowed with administrative autonomy. Portugal has 49 correctional facilities run by the Directorate-General for Reintegration and Prison Services (DGRSP). The facilities are classified by security level, and by degree of management complexity, and often house inmates with different legal statuses, risk levels, and criminal trajectories within the same facilities. Despite following a reintegration-oriented penal model, Portugal retains high prison occupancy and an average sentence length of 31.3 months and one of the world's highest prison suicide rates representing around 30% of the 60 to 70 deaths occurring annually.
== Inactivation == The study and manipulation of viruses, regardless of application, often requires a preceding inactivation step. The goal is to render the virus safe and non-infectious while preserving sufficient structural integrity to allow meaningful analysis. For serological studies, the preservation of surface epitopes is critical, as these protruding viral structures mediate antibody binding. Antigenicity is particularly important in vaccine development, where efficacy depends on eliciting a significant host immune response—especially the production of neutralizing antibodies. In contrast, for molecular studies the preservation of viral genetic material is prioritized, such as RNA or DNA, rather than surface structures. This requirement is central to many microbiological diagnostic methods, including PCR, other amplification techniques, and sequencing. Virus inactivation can be achieved through physical or chemical methods, and often a combination of approaches is employed. This is especially necessary when working with highly pathogenic viruses, where complete sterility is essential to eliminate the risk of exposure. Physical inactivation methods include heat (pasteurization), ultraviolet (UV) light, gamma radiation and pH-alteration inactivation. Chemical approaches encompass guanidinium-based chaotropic salts, detergents (e.g., sodium dodecyl sulfate [SDS], methanol, Tween compounds, Triton X-100), β-propiolactone, hydrogen peroxide, and aldehydes (e.g., formaldehyde, paraformaldehyde, glutaraldehyde), as well as aromatic disulfides.
Ritanserin, also known by its developmental code name R-55667, is a serotonin receptor antagonist which was under development for the treatment of anxiety disorders and major depressive disorder but was never marketed. It was also investigated for treatment of insomnia, especially to enhance sleep quality by significantly increasing slow wave sleep by virtue of potent and concomitant serotonin 5-HT2A and 5-HT2C receptor antagonism. The drug is taken orally.
Sources: en.wikipedia.org
creating non-viral transfection agents, developing preparations for biotechnological production and gene therapy; creating new programmable materials based on hybrid nanoparticles for medicine and biochemistry; developing direct synthesis methods, studying structure and properties of new sulphur derivatives of five-membered oxygen- and nitrogen-containing heterocycles; searching for chemo-, region- and stereo-selective thiating and aminating reactions with the view to create new antimicrobial agents based on studied heterocycles; developing new principles of pathogenic microflora control in collaboration with biologists. New organic synthesis methods are developed here, as well.
A NAD⁺-II class riboswitch, termed mini-NAD⁺-II, was first identified through iterative covariance model (CM) searches against representative bacterial genomes in the Genome Taxonomy Database. Mini-NAD⁺-II riboswitches lack the P1a stem and instead fold into a simple H-type pseudoknot, a compact RNA tertiary structure. The conserved nucleotides essential for tertiary contacts and specific recognition of the NMN moiety are retained, as is an A-rich tract following the P1 stem that likely forms a minor groove triplex. Mini-NAD⁺-II riboswitches lack the P1a stem and instead fold into a simple H-type pseudoknot, a compact RNA tertiary structure. The conserved nucleotides essential for tertiary contacts and specific recognition of the NMN moiety are retained, as is an A-rich tract following the P1 stem that likely forms a minor groove triplex. The potential for base pairing with the adjacent Shine–Dalgarno sequence is also retained, suggesting a conserved mechanism of translational regulation.
While indium-115 is very slightly radioactive, its half-life is longer than the age of the universe and indeed a typical sample of indium on earth will contain more of this "unstable" isotope than of "stable" indium-113.
=== July === 1 July – The ESA space telescope Euclid is launched, beginning a six-year mission to study dark energy and dark matter. 3 July – Researchers demonstrate encoding and storing data – small images – as DNA without new DNA synthesis by recording light exposure into bacterial DNA via optogenetic circuits. The 'biological camera' extends chemical and electrical interface techniques. 5 July Harvard astronomer Avi Loeb reports the possibility of a Galileo project expedition having found first interstellar material. A first evolution experiment of synthetic 'minimal cells' – JCVI-syn3B bacterial cells whose genomes were trimmed to 493 essential genes and are the smallest of any known free-living organism – shows they survive and mutate vitally with their >50% decrease in fitness to JCVI-syn1 being regained after ~2,000 generations under accelerated evolution. 6 July – A study indicates release of methane from Arctic glacial retreat will result in Arctic emissions much higher than expected.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.